Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:BEDZNYSEARCA:FNTCNYSEARCA:RNDNASDAQ:XDNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEDZAdvisorShares Hotel ETF$31.54+1.5%$29.62$24.59▼$34.94$2.68M1.1804 shs506 shsFNTCDirexion Daily Fintech Bull 2X Shares$12.75$12.75$9.69▼$23.69$2.55M2.762,255 shsN/ARNDFirst Trust Bloomberg R&D Leaders ETF$26.69+0.7%$24.72$19.84▼$26.69$2.67MN/A775 shs3,256 shsXDNAKelly CRISPR & Gene Editing Technology ETF$7.38$7.38$5.87▼$11.83$2.21M0.923,034 shsN/AMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEDZAdvisorShares Hotel ETF0.00%+4.54%+4.96%+9.21%+12.35%FNTCDirexion Daily Fintech Bull 2X Shares0.00%0.00%0.00%0.00%0.00%RNDFirst Trust Bloomberg R&D Leaders ETF0.00%+4.67%+5.62%+18.36%+18.71%XDNAKelly CRISPR & Gene Editing Technology ETF0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBEDZAdvisorShares Hotel ETFN/AN/AN/AN/AN/AN/AN/AN/AFNTCDirexion Daily Fintech Bull 2X SharesN/AN/AN/AN/AN/AN/AN/AN/ARNDFirst Trust Bloomberg R&D Leaders ETFN/AN/AN/AN/AN/AN/AN/AN/AXDNAKelly CRISPR & Gene Editing Technology ETFN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEDZAdvisorShares Hotel ETF 2.55Moderate Buy$31.54N/AFNTCDirexion Daily Fintech Bull 2X Shares 0.00N/AN/AN/ARNDFirst Trust Bloomberg R&D Leaders ETF 2.78Moderate Buy$26.69N/AXDNAKelly CRISPR & Gene Editing Technology ETF 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEDZAdvisorShares Hotel ETFN/AN/AN/AN/AN/AN/AFNTCDirexion Daily Fintech Bull 2X SharesN/AN/AN/AN/AN/AN/ARNDFirst Trust Bloomberg R&D Leaders ETFN/AN/AN/AN/AN/AN/AXDNAKelly CRISPR & Gene Editing Technology ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEDZAdvisorShares Hotel ETFN/AN/A16.44∞N/AN/AN/AN/AN/AFNTCDirexion Daily Fintech Bull 2X SharesN/AN/A15.81∞N/AN/AN/AN/AN/ARNDFirst Trust Bloomberg R&D Leaders ETFN/AN/A34.30∞N/AN/AN/AN/AN/AXDNAKelly CRISPR & Gene Editing Technology ETFN/AN/A17.02∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBEDZAdvisorShares Hotel ETF$0.461.46%N/AN/AN/AFNTCDirexion Daily Fintech Bull 2X Shares$0.040.31%N/AN/AN/ARNDFirst Trust Bloomberg R&D Leaders ETF$0.010.04%N/AN/AN/AXDNAKelly CRISPR & Gene Editing Technology ETFN/A0.12%N/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEDZAdvisorShares Hotel ETFN/AFNTCDirexion Daily Fintech Bull 2X SharesN/ARNDFirst Trust Bloomberg R&D Leaders ETFN/AXDNAKelly CRISPR & Gene Editing Technology ETFN/AInsider OwnershipCompanyInsider OwnershipBEDZAdvisorShares Hotel ETFN/AFNTCDirexion Daily Fintech Bull 2X SharesN/ARNDFirst Trust Bloomberg R&D Leaders ETFN/AXDNAKelly CRISPR & Gene Editing Technology ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEDZAdvisorShares Hotel ETFN/A85,000N/ANot OptionableFNTCDirexion Daily Fintech Bull 2X SharesN/A200,000N/ANot OptionableRNDFirst Trust Bloomberg R&D Leaders ETFN/A100,000N/AN/AXDNAKelly CRISPR & Gene Editing Technology ETFN/A300,000N/AOptionableBEDZ, RND, FNTC, and XDNA HeadlinesRecent News About These CompaniesCHOP, Penn advance CRISPR gene editing with fast-developed treatment for an infant with a rare diseaseMay 15, 2025 | msn.comNobel Prize winners convince court to revive CRISPR patent disputeMay 12, 2025 | reuters.comBiotech investors: Stop expecting CRISPR science to make big leapsApril 14, 2025 | statnews.comSAI and gene editing promise ‘bespoke proteins’ for biotechOctober 8, 2024 | siliconrepublic.comSWeight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right nowOctober 2, 2024 | yahoo.comK-12 Genome Editing at Only $2 a PopSeptember 27, 2024 | yahoo.comVertex Stock: Came For CF Drugs, Staying For Gene TherapyAugust 2, 2024 | seekingalpha.comCRISPR can treat common form of inherited blindness, early data hintMay 15, 2024 | msn.comCRISPR gene editing: in summaryMarch 27, 2024 | biotechniques.comBCRISPR Technology Takes Center Stage at SXSW 2024 for the First TimeMarch 8, 2024 | markets.businessinsider.comIntellia Collaborates With ReCode To Develop Gene Therapy For Cystic FibrosisFebruary 15, 2024 | markets.businessinsider.comCRISPR Technology: Unveiling the Breakthrough in Gene Editing and Its Far-Reaching ImplicationsJanuary 18, 2024 | techbullion.comTHere's Why CRISPR Therapeutics Stock Rose 54% Last YearJanuary 15, 2024 | msn.comGene editing is now a medical realityDecember 8, 2023 | news.yahoo.comFDA approves first use of CRISPR gene editing to treat sickle cell diseaseDecember 8, 2023 | news.yahoo.comFDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood DisorderDecember 8, 2023 | markets.businessinsider.comGene Editing Will Change Medicine—and Maybe Health Investing TooNovember 24, 2023 | msn.comCRISPR/Cas9 unlocks TuMV resistance in Chinese cabbage: A leap forward in genome-edited plant breedingNovember 23, 2023 | phys.orgPIs CRISPR Therapeutics the Best Gene-Editing Stock?November 22, 2023 | msn.comThree people were gene-edited in an effort to cure their HIV. The result is unknown.November 16, 2023 | technologyreview.comTMedia Sentiment Over TimeBEDZ, RND, FNTC, and XDNA Company DescriptionsAdvisorShares Hotel ETF NYSEARCA:BEDZ$31.54 +0.47 (+1.51%) As of 06/27/2025 04:10 PM EasternThe AdvisorShares Hotel ETF (BEDZ) is an exchange-traded fund that mostly invests in consumer discretionary equity. The fund is an actively managed ETF that provides exposure to US hotels, resorts, cruise lines and their sub-industries. BEDZ was launched on Apr 20, 2021 and is managed by AdvisorShares.Direxion Daily Fintech Bull 2X Shares NYSEARCA:FNTC$12.75 0.00 (0.00%) As of 02/24/2023The Direxion Daily Fintech Bull 2X Shares (FNTC) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund offers 2x daily leveraged exposure to an index of US-listed equities that offer financial technology services and decentralized finance systems. The index is selected and weighted by market-cap. FNTC was launched on Jan 20, 2022 and is managed by Direxion.First Trust Bloomberg R&D Leaders ETF NYSEARCA:RND$26.69 +0.19 (+0.72%) As of 06/27/2025 04:10 PM EasternThe First Trust Bloomberg R&D Leaders ETF (RND) is an exchange-traded fund that is based on the Bloomberg R&D Leaders Select TR index. The fund tracks a market cap-weighted index of 30-50 US stocks with substantial expenditures dedicated to research and development. RND was launched on Apr 30, 2024 and is issued by First Trust.Kelly CRISPR & Gene Editing Technology ETF NASDAQ:XDNA$7.38 0.00 (0.00%) As of 06/27/2025The Strategic CRISPR & Gene Editing Technology ETF (XDNA) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market-cap-weighted index of companies in developed markets that focus on the advancements in DNA modification technology. XDNA was launched on Jan 12, 2022 and is managed by Kelly. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
